COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation
17/07/2025
Second-Quarter and First-Half 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial [...]
EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation
17/07/2025
Second-Quarter and First-Half 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial [...]
MYOS PET and Leading Veterinarian Urge Action as Weather Extremes Impact Senior Pet Muscle Health
17/07/2025
CEDAR KNOLLS, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- With climate changes becoming more severe, veterinary sports medicine and rehabilitation expert Dr. Kelly Fishman, DVM, CVA, CCRT, warns that summer heat waves and [...]
Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
17/07/2025
WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on [...]
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
17/07/2025
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call
17/07/2025
ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August [...]
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
17/07/2025
The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE [...]
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
17/07/2025
Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for [...]
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
17/07/2025
Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously [...]
Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink
17/07/2025
BRECKENRIDGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery , an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce the launch [...]
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
17/07/2025
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle [...]
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
17/07/2025
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA [...]
Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache
17/07/2025
DURHAM, N.C., July 17, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies (“Palantir”) to [...]
Repligen to Report Second Quarter 2025 Financial Results
17/07/2025
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second [...]
Peptides For Muscle Growth: How Oral Legal Peptides by Crazy Bulk Set New Benchmark For Bodybuilding Supplements and Muscle Building Results
17/07/2025
Discover how CrazyBulk’s oral legal peptides and SARMs stacks are redefining muscle building supplements in 2025. Explore science-backed, gym-proven solutions for bodybuilders seeking faster recovery, leaner muscle [...]
KFSHRC Performs World’s First Robotic-Assisted BiVAD Implantation
17/07/2025
A minimally invasive robotic surgery offers a life-saving option for high-risk patients who cannot undergo transplants or traditional open-heart procedures RIYADH, Saudi Arabia, July 17, 2025 (GLOBE NEWSWIRE) -- King [...]
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
17/07/2025
Milestone payment of $10 million triggered under the global license agreement with Takeda LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage [...]
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
17/07/2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) [...]
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
17/07/2025
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The EMBOLD cohort 2 [...]

Pages